Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwood Reduction Act of 55, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 146464545

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

C	omplete if Known
Application Number	10/005,996
Filing Date	December 3, 2001
First Named Inventor	William M. Partridg
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	407T-994110US
Date Submitted	November 11, 2003

U.S. PATENT DOCUMENTS										
U.S. Patent Document Name of Patentee or Applicant of Date of Publication of Pages										
Cite No.	Number	Kind Code (if known)	Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appeal					
1		-								
		Cite Number	U.S. Patent Document Cite Number Kind Code	U.S. Patent Document Name of Patentee or Applicant of Cited Number Kind Code Cited Document	U.S. Patent Document Name of Patentee or Applicant of Cited Document Cited Document Cited Document					

				FOREIGN	N PATENT DOCUMEN			<del>,</del> .
		F	oreign Patent Docur	nent		Date of Publication	Pages, Columns, Lines,	_
Examiner Initials	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	
								_
					_			

			OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
r	Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
_	M	01	BOADO et al. (1998) "Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS." J. Pharm. Sci. 87:1308-1315.	
				<u> </u>
				ļ
				ļ
				_

(1112		<u> </u>	<u> </u>
Examiner Signature	Date Considered	10/(9/	64
			•

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. CMB 0651-0031

Substitute for form 1449A-B/PTO	C	omplete if Known				Q
	Application Number	10/005,996		A		
P ENFORMATION DISCLOSURE	Filing Date	December 3, 2001	N	36		Ì
STAGEMENT BY APPLICANT	First Named Inventor	William M. Partridge	_ ∰	N		ノ ユ
<b>/</b>	Group Art Unit	1645		9		1
AUG 2 3 2002 55	Examiner Name	Unassigned	80	20		<b>.</b>
(yet as many sheets as necessary)	<b>Attorney Docket Number</b>	407T-994110US	8	02		
CAT BEET STORY	Date Submitted		9			
& TRANE			9		J	

Cite No.	Number	I Idiad Cada			Pages, Columns, lines,
	· · · · · · · · · · · · · · · · · · ·	Kind Code (if known)	Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appeal
01	4,801,575		Pardridge	01-31-1989	
)2	4,902,505		Pardridge et al.	02-20-1990	
03	6,287,792	B1	Pardridge et al.	09-11-2001	
)2	2	2 4,902,505	2 4,902,505	2 4,902,505 Pardridge et al.	2 4,902,505 Pardridge et al. 02-20-1990

		<del>.</del>		FOREIGN	N PATENT DOCUMEN	TS		
			Foreign Patent Docu	ment		Date of Publication	Pages, Columns, Lines,	
Examiner Initials	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	
TEK	04	EP	0 592 564	B1				

(			OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	, <u> </u>
	Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	M	05	Agrawal et al. (1991) Proc. Natl. Acad. Sci., USA, 88:7595-7599.	
4	in	06	Boado and Pardridge (1994) Bioconj. Chem., 6: 406-410	
-	M	07	Boado and Pardridge (1998) Mol. Brain Res. 59: 109-113.	
	M	08	Boado et al. (1999) Proc. Natl. Acad. Sci., USA, 96: 12079-12084.	
	The	99	Boado et al. (2000) J. Pharmacol. Exp. Ther., 295: 239-243.	
	N	10	Brown et al. (1994) J. Biol. Chem., 269:26801-26805.	
	M	11	Chem et al. (1990) Drug Metab. Dispos. 18:518-818. CHEN ET AL.	
	N	12	Chinnery et al. (1999) Gene Ther. 6: 1919-1928.	
i	11/	13	Coloma et al. (2000) Pharm. Res. 17:266-274.	
	j	14	Cossum et al. (1993) J. Pharmacol. Exp. Ther., 267: 1181-1190.	
		15	Crookie (1993) FASEB J. 7:533-539.	
		16	de Smidt et al. (1991) Nucleic Acids Res. 19: 4695-4700.	
	1	17	Demidov et al. (1994) Biochem. Pharmacol. 48: 1310-1313.	
4	VI	18	Gee et al. (1998) Antisense and Nucleic Acid Drug Develop. 8:103-111.	

Examiner Date Date					1	<u></u>	
Signature Considered Considered	Examiner	total.	1	0	19/	'orl	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	4 4444 5 574	T	omplete if Known	
Substitute fo	or form 1449A-B/PTO	Application Number	omplete if Known 10/005,996	
INFORM/	ATION DISCLOSURE	Filing Date	December 3, 2001	<u>S</u>
	ENT BY APPLICANT	First Named Inventor	William M. Partridge	0 3
, oct		Group Art Unit	1645	
3 2000 (mg as	s many sheets as necessary)	Examiner Name Attorney Docket Number	Unassigned 407T-994110US	₩ %
S DE LE	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Date Submitted	40/1-33411003	
		T Date Castillities		200
19	Hanvey et al. (1992) Science.	, 258:1481-1486.		/2980
20	Heffetz et al. (1989) Eur. J. Bi	ochem. 182:343-348.		6
21	Hnatowich (1999) J. Nucleic N	леd. 40: 693–703.		
W 22	Huwyler and Pardridge (1998)	) J. Neurochem. 70:883-88	6.	
M 23	Kang et al.(1995) Drug Metab	. Dispos. 23: 55–59.		
24	Kirupa et al. (1999) Phil. Tran	s. R. Soc. Lond., 354: 963-	969. SATHASIVAM	EÍ AL.
25	Kobori et al. (1999) NeuroRep	port 10: 2971–2974.		
W 26	Krieg et al. (1993) Proc. Natl.	Acad. Sci., USA, 90: 1048-	-1052.	
W 27	Kurihara and Pardridge (1999	) Cancer Res. 54: 6159-61	<b>63</b> .	
28	Kurihara et al. (1999) Bioconji	ugate Chem. 10: 502-511.		
29	Lee et al. (2000) J. Pharmaco	ol. Exp Ther. 292:1048-1052	2.	
W 30	Li et al. (1999) Protein Engine	ering 12:787-796.		
31	Lockhart and Winzeler (2000	) Nature., 405: 827-836		
W 32	Mash et al. (1990) J. Neuroch	iem. 55: 1972–1979.		
TW 33	Mayfield and Corey (1999) A	nal. Biochem., 268: 401-40	4.	
W 34	Nielsen et al. (1994) Bioconju	igate Chem. 5: 3-7.		
35	Pardridge (2001) Drug Disco	very Today., 6: 104-106		
36	Pardridge (1997) J. Cereb. Bl	ood Flow Metabol. 17:713-	731. ° <b>≫</b> ()	
Jh 37	Pardridge et al. (1995) Pharm	n. Res. 12:807-816.		
723 38	Pardridge et al. (1995)Proc. N	Vatl. Acad. Sci., USA, 92:55	592-5596. 	
)39	Penichet et al. (1999) J. Immi	unol. 163:4421-4426.		
40	Rebert et al. (1990) Pharmac	ol. Biochem. Behav. 36: 35	1–356.	
77 41	Rockwell et al. (1997)Proc. N	atl. Acad. Sci., USA, 94:65	23-6528.	
NW 42	Samii et al. (1994) Am. J. Phy	ysiol., 267: E124-E134.		
Jh 43	Shechter et al. (1982) Nature	216:542-545.		
JU 44	Shi and Pardridge (2000) Pro	c. Natl. Acad. Sci., USA, 97	7, 7567–7572.	
45	Shi et al. (2000) Proc. Natl. A	cad. Sci., USA, 97: 14709-	14714.	
JA 46	Skarlatos et al. (1995) Brain	Res., 683: 164-171		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



(Modified) PTO/SB/08A-B (10-96) Approved for use through 10/31/99. OMB 0651-0031

		AUG 2 3 COUL ES		pproved for use through 10/31/99.	O 1410 000 17	1001	
Sub	stitute fo	or form 1449 AB/PTO	Co	omplete if Known			
100		ATION DISCLOSURE ENT BY APPLICANT	Application Number	10/005,996			
SILL BUE	<b>B</b> RMA	ATION DISCLOSURE	Filing Date	December 3, 2001	_ 오		
STA	MAST	ENT BY APPLICANT	First Named Inventor	William M. Partridge		A	
2 3 200			Group Art Unit	1645	m	AUG	
1 1 2 ma	2-1	s many sheets as necessary)	Examiner Name	Unassigned		22	
	70	many sneets as necessary)	Attorney Docket Number	407T-994110US	- 33	6	
TRANES	<u>~</u>		Date Submitted			2	
TRAILE		T	<del>-</del>		8	2002	
Th	47	Stein and Cheng (1993) Scien	ce 261:1004-1012.		/290		
In	48	Tavitian et al. (21998) Nat. Me	d., 4: 467-471		0		
171	49	Tsukamoto et al. (1997) J. Net	urochem. 68: 2587-2592.				
Jw.	50	Tyler et al. (1999) Proc. Natl. Acad. Sci., USA, 96: 7053-7058.					
w	51	Ueda et al. (1993) J. Neuroche	em. 60: 106–113.				
Th	52	Whitesell et al. (1993) Proc. No.	atl. Acad. Sci., USA, 90: 466	55–4669.			
m	53	Wickstrom (1986) J. Biochem.	Biophys. Methods 13:97-10	2.			
TU	54	Wittung et al. (1994) Nature 36	88:561-563.				
Ju	55	Wojcik et al. (1996) J. Pharma	Wojcik et al. (1996) J. Pharmacol. Exp. Ther. 278:404-410.				
M.	56	Wu et al. (1996) J. Pharmacol	Exp. Ther., 276: 206-211.				
	57	Zendegui et al. (1992) Nucleic	Acids Res. 20:307-314.		· · · · · · · · · · · · · · · · · · ·		
XV	58	Zhang and Pardridge (2001) J.	Neurochem., 76: 1597-160	0.	_		
The same of the sa	59	Zhao et al. (1999) J. Biol. Cher	n. 274: 34893–34902.				
MM	60	Zick et al. (1984) J. Biol. Chem	. 259:4396-4400.				

	 17 A 3		-
Examiner		Date	11/0/61
Signature	1) Color	Considered	(0)/9/09